Welcome to our dedicated page for Verve Therapeutics news (Ticker: VERV), a resource for investors and traders seeking the latest updates and insights on Verve Therapeutics stock.
Verve Therapeutics, Inc. (VERV) is a clinical-stage biotechnology pioneer developing single-course gene editing treatments for cardiovascular disease. This news hub provides investors and healthcare professionals with essential updates on therapeutic advancements, clinical trial progress, and strategic developments.
Access comprehensive coverage of VERV's innovative pipeline including PCSK9, ANGPTL3, and LPA gene editing programs. Our curated news collection features regulatory milestones, partnership announcements, and scientific breakthroughs in base editing technology.
Stay informed about Verve's cutting-edge approach to permanently modifying cholesterol-related genes through precise liver-targeted therapies. The page aggregates official press releases, trial result analyses, and expert commentary while maintaining strict financial compliance standards.
Bookmark this page for real-time updates on Verve Therapeutics' mission to transform cardiovascular care through durable genetic medicines. Check regularly for new developments in this rapidly evolving sector of precision biotechnology.
Verve Therapeutics reported significant advancements, including over $300 million added to its balance sheet, supporting operations well into the second half of 2025.
VERVE-101, aimed at treating heterozygous familial hypercholesterolemia, initiated patient dosing with interim clinical data expected in 2023. Regulatory clearances in the UK and US are anticipated soon.
The company also nominated VERVE-201 for ANGPTL3 treatment, with upcoming data presentations and IND-enabling studies in the pipeline. Additionally, new board members were appointed to bolster strategic growth.
Verve Therapeutics (Nasdaq: VERV) has successfully closed an upsized public offering of 9,583,334 shares at $27.00 per share, generating gross proceeds of $258.8 million. The offering's total includes 1,250,000 shares from underwriters' exercised options. Shares were sold under a shelf registration statement approved by the SEC. This financing aims to advance Verve's gene editing therapies targeting cardiovascular disease.
Verve Therapeutics, Inc. (Nasdaq: VERV) announced an upsized underwritten public offering of 8,333,334 shares of its common stock priced at $27.00 each, aiming for approximately $225 million in gross proceeds. The offering, fully underwritten, is set to close on July 25, 2022, subject to customary conditions. Additionally, underwriters may purchase up to 1,250,000 additional shares. Verve plans to utilize the funds to advance its gene editing therapies targeting cardiovascular disease, particularly focusing on PCSK9 and ANGPTL3.
Verve Therapeutics (Nasdaq: VERV) has initiated an underwritten public offering of $200 million in common stock. The offering includes an option for underwriters to purchase up to an additional 15% of the shares, subject to market conditions. The company is leveraging a shelf registration statement effective as of July 12, 2022. This offering aims to support Verve's innovative approach to addressing cardiovascular disease through single-course gene editing, targeting genes like PCSK9 and ANGPTL3.
Verve Therapeutics has announced a collaboration with Vertex Pharmaceuticals, securing a $60 million upfront payment, which includes a $35 million equity investment. The partnership aims to develop an in vivo gene editing program targeting a specific liver disease over four years. Vertex will finance the research, while retaining rights to future development and commercialization. Verve could also earn up to $406 million in milestone payments and royalties on potential net sales. This collaboration marks a pivotal step in Verve's ongoing efforts to innovate gene editing therapies for cardiovascular diseases.
Verve Therapeutics announces the start of the Phase 1b clinical trial, heart-1, for its investigational gene editing medicine, VERVE-101, aimed at treating patients with heterozygous familial hypercholesterolemia (HeFH). The first patient has been dosed, marking a significant milestone in its development. VERVE-101 seeks to permanently deactivate the PCSK9 gene in the liver to reduce low-density lipoprotein cholesterol (LDL-C) levels. The trial plans to enroll around 40 participants, with interim data expected in 2023.
Verve Therapeutics has appointed Alexander G. “Bo” Cumbo, former CEO of AavantiBio, to its board of directors. Cumbo, who has over 28 years of experience in the pharmaceutical industry, brings a wealth of expertise in drug development and commercial execution. His appointment comes as Verve advances its regulatory strategy for VERVE-101 and its second program targeting ANGPTL3. The company aims to transform cardiovascular disease treatment from chronic management to single-course therapies, with VERVE-101 targeting familial hypercholesterolemia.
Verve Therapeutics will showcase its innovative approach to treating cardiovascular disease at the 2022 Jefferies Healthcare Conference. Co-founder and CEO Sekar Kathiresan will speak on June 8, 2022, at 1:00 p.m. ET in NYC. The company focuses on single-course gene editing medicines, specifically targeting PCSK9 and ANGPTL3 genes to lower LDL cholesterol levels. Verve’s lead candidate, VERVE-101, aims to reduce cardiovascular risk by permanently turning off the PCSK9 gene in the liver. A live webcast will be available on their investor website and archived for 60 days.
Verve Therapeutics has announced its strategic advancements for VERVE-101, aiming to treat heterozygous familial hypercholesterolemia (HeFH). The company has received clinical trial application clearance in New Zealand, with plans for a Phase 1 trial to start mid-2022 and initial data expected in 2023. Additionally, they are preparing regulatory submissions in the UK and US by late 2022. As of March 31, 2022, Verve holds $323.3 million in cash, providing a cash runway through 2024.
Verve Therapeutics announced significant results from its VERVE-101 program targeting heterozygous familial hypercholesterolemia (HeFH). The preclinical data revealed a mean 68% reduction in plasma LDL-C in non-human primates (NHPs) after a single intravenous infusion, with results sustained for up to one year. The administration was well-tolerated, and the GalNAc-Lipid Nanoparticle technology showed improved delivery potency, achieving a 98% reduction in blood ANGPTL3 after 15 days. Verve aims for global regulatory submissions this year to advance VERVE-101 into clinical trials.
